Dr Lalchandani Labs Share Price | Dr Lalchandani Labs Stock Screener
DLCL
Healthcare Service Provider
Track Dr Lalchandani Labs share price live with TickJournal's free stock screener.
Check DLCL 52-week performance for the annual price range and momentum.
Use the Dr Lalchandani Labs stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Dr Lalchandani Labs Market Cap
₹8.17 Cr.
DLCL P/E Ratio (TTM)
-
Dr Lalchandani Labs P/B Ratio
0.58
EPS (TTM)
₹0.96
Dividend Yield
-
Debt to Equity
0.39
DLCL 52 Week High
-
Dr Lalchandani Labs 52 Week Low
-
Operating Margin
-
Profit Margin
-
DLCL Revenue (TTM)
-
EBITDA
-
Net Income
-
Total Assets
₹16.00
Total Equity
₹10.00
Dr Lalchandani Labs Share Price Chart
Screen Dr Lalchandani Labs share price with an interactive chart. Analyse DLCL price trends and volatility across different timeframes.
Dr Lalchandani Labs Company Profile - Fundamental Screener
Screen Dr Lalchandani Labs company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for DLCL shares.
Sector
Healthcare Services
Industry
Healthcare Service Provider
Sub-Sector
Healthcare Service Provider
Segment
E
ISIN
INE871Z01013
Dr Lalchandani Labs Balance Sheet Screener
Screen DLCL balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Total Assets | 16 | 15 | 18 | 18 | 15 | 12 | 10 | 6 |
| Current Assets | 11 | 10 | 11 | 11 | 9 | 8 | 6 | 4 |
| Fixed Assets | 4 | 4 | 5 | 6 | 5 | 4 | 3 | 2 |
| Liabilities | ||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 0 | 0 | 4 | 3 | 3 | 2 | 1 | 1 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||
| Total Equity | 10 | 10 | 9 | 11 | 10 | 9 | 8 | 3 |
| Share Capital | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 |
| Reserves & Surplus | 6 | 5 | 5 | 6 | 5 | 4 | 4 | 0 |
Dr Lalchandani Labs Income Statement Screener - Profit & Revenue Analysis
Screen Dr Lalchandani Labs income statement and profit fundamentals.
Analyze DLCL quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Dr Lalchandani Labs share price evaluation.
| Item | None-None | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 5 | 5 | 5 | 11 | 10 | 6 | 5 | 3 |
| Expenses | 0 | 4 | 5 | 5 | 9 | 8 | 5 | 4 | 2 |
| EBITDA | 0 | 1 | 0 | 0 | 2 | 2 | 1 | 1 | 1 |
| Operating Profit % | 0.00% | 21.00% | 4.00% | 2.00% | 21.00% | 23.00% | 21.00% | 23.00% | 22.00% |
| Depreciation | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 0 | 0 | 1 | -2 | 1 | 1 | 1 | 1 | 0 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | 0 | 0 | 1 | -2 | 1 | 1 | 1 | 1 | 0 |
| EPS | 0.00 | 0.96 | 1.43 | -3.61 | 2.15 | 2.33 | 1.09 | 1.23 | 0.89 |
Dr Lalchandani Labs Cash Flow Screener - Liquidity Fundamentals
Screen DLCL cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 1 |
| Investing Activities | 0 | 1 | 0 | -2 | -2 | -1 | -2 | -1 |
| Financing Activities | 1 | -2 | 0 | 0 | 2 | 1 | 4 | 2 |
| Net Cash Flow | 1 | -1 | 0 | 1 | 1 | 0 | 1 | 1 |
Dr Lalchandani Labs Shareholding Pattern Screener
See Dr Lalchandani Labs shareholding pattern with promoter, FII, and DII holdings.
Check Dr Lalchandani Labs promoter holding and ownership changes for DLCL on TickJournal.
| Item | 2026-Mar | 2025-Mar | 2025-Sept | 2024-Mar | 2024-Sept | 2023-Mar | 2023-Sept | 2022-Mar |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 32.90% | 48.32% | 31.15% | 60.78% | 57.18% | 60.78% | 60.78% | 60.78% |
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 62.74% | 45.68% | 64.51% | 32.94% | 36.54% | 32.75% | 33.03% | 33.58% |
| Other Holding | 4.35% | 6.00% | 4.34% | 6.28% | 6.28% | 6.46% | 6.18% | 5.63% |
| Shareholder Count | 234 | 246 | 206 | 165 | 181 | 162 | 159 | 151 |
Dr Lalchandani Labs Share Dividend Screener - Share Yield Analysis
Check Dr Lalchandani Labs dividend history with payout and yield data.
View Dr Lalchandani Labs dividend details including ex-dates and amounts for DLCL stock.
Dr Lalchandani Labs Stock Index Membership
See which indices include Dr Lalchandani Labs stock.
Check DLCL index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Dr Lalchandani Labs Market Events Screener - Corporate Actions
Get Dr Lalchandani Labs corporate actions including splits, bonuses, and buybacks.
Check Dr Lalchandani Labs stock events that may affect DLCL share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | -9.31% | ||
| Annual General Meeting | NA | -12.60% | ||
| 2026-01-27 | 2026-01-27 | Rights | 1:1 | -11.76% |
| 2025-11-14 | 2025-11-14 | Quarterly Result Announcement | NA | -5.02% |
| 2025-05-01 | 2025-05-01 | Quarterly Result Announcement | NA | -6.12% |
| 2024-10-14 | 2024-10-14 | Quarterly Result Announcement | NA | 5.14% |
Dr Lalchandani Labs Competitors Screener - Peer Comparison
Screen DLCL competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Dr. Lal Path Labs | 26,876 | 53.50 | 2,763 | 8.15% | 510 | 55.66 |
| Vijaya Diagnostic Centre | 12,961 | 72.87 | 814 | 16.36% | 182 | 60.54 |
| Metropolis Healthcare | 11,213 | 56.27 | 1,646 | 22.25% | 185 | 62.69 |
| Thyrocare Technologies | 7,994 | 45.59 | 829 | 18.06% | 156 | 71.28 |
| Nephrocare Health Services | 6,092 | 79.31 | 999 | 29.74% | 62 | 56.47 |
| Krsnaa Diagnostics | 1,781 | 22.68 | 743 | 16.70% | 78 | 32.60 |
| Suraksha Diagnostic | 1,539 | 51.38 | 310 | 21.30% | 34 | 51.56 |
| 3B BlackBio DX | 1,028 | 17.70 | 112 | 28.72% | 48 | 41.85 |
| Health X Platform | 999 | 33.22 | 1,171 | -18.47% | -134 | 64.03 |
| One Global Service Provider | 852 | 14.18 | 148 | 134.60% | 19 | 40.48 |
Dr Lalchandani Labs Company Announcements - News Screener
Screen DLCL latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-05-04 | Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2 | - |
| 2026-04-30 | Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A | - |
| 2026-04-22 | Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer | - |
| 2026-04-13 | Reply To The Clarification Sought By BSE | - |
| 2026-04-13 | Clarification sought from Dr Lalchandani Labs Ltd | - |
| 2026-04-09 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-03-27 | Closure of Trading Window | - |
| 2026-03-06 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-03-05 | Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011 | - |
| 2026-03-02 | Approval Of Basis Of Allotment Under Right Issue | - |
| 2026-03-02 | Board Meeting Outcome for Outcome Of Board Meeting Held On Monday March 02 2026 | - |
| 2026-02-17 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-02-16 | Board Meeting Revised Outcome For Extension Of Issue Period | - |
| 2026-02-16 | Board Meeting Outcome for Board Meeting Outcome For Extension Of Issue Period | - |
| 2026-02-03 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-01-31 | Newspaper Publication Under Regulation 84(1) Of SEBI (ICDR) Regulations | - |
| 2026-01-21 | Letter Of Offer For Rights Issue Of Equity Shares | - |
| 2026-01-20 | Intimation Of Record Date Pursuant To Regulation 42 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-01-20 | Announcement under Regulation 30 (LODR)-Raising of Funds | - |
| 2026-01-20 | Revised Outcome Of The Board Meeting Held On January 20 2026 For Approving Terms Of Rights Issue | - |